NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

INTERIM FINANCIAL STATEMENTS

JUNE 30, 2026

เลขที่ 5/1 ศุภาลัย แกรนด์ เอสเซ้นส์
ถนนรัชดาภิเษก แขวงวัดท่าพระ
เขตบางกอกใหญ่ กรุงเทพฯ 10600
โทร. 02-125-0029
093-130-8984
093-130-8986
อีเมล์ virach_asso@vaaudit.com

V & A
บริษัท สำนักงาน ดร.วิรัช แอนด์ แอสโซซิเอทส์ จำกัด
DR.VIRACH & ASSOCIATES OFFICE CO., LTD.
CERTIFIED PUBLIC ACCOUNTANTS
สำนักงานใหญ่ เลขประจำตัวผู้เสียภาษี 0105556000751

5/1 Supalai Grand Essence Village,
Ratchadapisek Road, Khwaeng Wat Tha Phra,
Khet Bangkok Yai, Bangkok 10600
Tel. 66 (0)2-125-0029
66 (0)93-130-8984
66 (0)93-130-8986
Email virach_asso@vaaudit.com

INDEPENDENT AUDITOR'S REPORT ON REVIEW OF FINANCIAL INFORMATION

To : The Shareholders and The Board of Directors of

Nonthavej Hospital Public Company Limited

I have reviewed the accompanying statements of financial position of Nonthavej Hospital Public Company Limited as at June 30, 2026, the related statements of comprehensive income for the three-month and six-month periods ended June 30, 2026, changes in shareholders' equity and cash flows for the six-month period then ended, and the condensed notes to the financial statements. Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 : Interim Financial Reporting. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of review

I conducted my review in accordance with the Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 : Interim Financial Reporting.

Suvimol Sriprapakorn

(Ms. Suvimol Sriprapakorn)

Certified Public Accountant Registration No. 8351

Dr.Virach & Associates Office Co., Ltd.

Bangkok : August 11, 2026

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF FINANCIAL POSITION

AS AT JUNE 30, 2026

ASSETS

		THOUSAND BAHT	
		As at June 30, 2026	As at December 31, 2025
	Notes	UNAUDITED REVIEWED	AUDITED
Current Assets			
Cash and cash equivalents	*4*	1,061,686	1,111,363
Trade and other current receivable	*5*	245,130	267,519
Inventories	*6*	61,656	60,207
Other current financial assets			
Investments in Open-ended Fund	*7.1*	30	23
Marketable securities	*7.2*	988	772
Total other current financial assets		1,018	795
Current portion of other non-current financial assets			
Other investment	*8.2*	275,000	150,000
Other current assets		1,132	1,233
Total Current Assets		1,645,622	1,591,117
Non-current Assets			
Other non-current financial assets			
Marketable securities	*8.1*	5,176	5,291
Other investment	*8.2*	-	125,000
Fixed deposit at bank	*8.3*	100,000	120,000
Total other non-current financial assets		105,176	250,291
Property, plant and equipment		1,273,068	1,297,340
Intangible assets		10,422	11,072
Deferred tax assets	*12*	18,741	17,719
Other non-current assets		4,965	5,685
Total Non-current Assets		1,412,372	1,582,107
TOTAL ASSETS		3,057,994	3,173,224

Suumnd.

Notes to the interim financial statements form an integral part of these statements.

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF FINANCIAL POSITION

AS AT JUNE 30, 2026

LIABILITIES AND SHAREHOLDERS' EQUITY

		THOUSAND BAHT	
		As at June 30, 2026	As at December 31, 2025
	Notes	UNAUDITED REVIEWED	AUDITED
Current Liabilities			
Trade and other current payables	*9*	210,724	218,191
Assets acquisition payable		8,165	25,591
Accrued corporate income tax		10,251	23,309
Other current liabilities		8,045	8,045
Total Current Liabilities		237,185	275,136
Non-current Liabilities			
Non-current provisions for employee benefits	*10*	88,062	81,004
Total Non-current Liabilities		88,062	81,004
TOTAL LIABILITIES		325,247	356,140
Shareholders' Equity			
Share capital			
Authorized share capital			
160,000,000 common stocks of Baht 1 par value		160,000	160,000
Issued and paid-up share capital			
160,000,000 common stocks at Baht 1 each		160,000	160,000
Additional paid-in capital			
Premium on common stocks		172,000	172,000
Retained earnings			
Appropriated			
Legal reserve		16,000	16,000
Unappropriated		2,360,181	2,444,426
Other components of shareholders' equity		24,566	24,658
Total Shareholders' Equity		2,732,747	2,817,084
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		3,057,994	3,173,224

Notes to the interim financial statements form an integral part of these statements.

UNAUDITED

REVIEWED

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF COMPREHENSIVE INCOME

FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2026

		THOUSAND BAHT			
		EXCEPT EARNINGS PER SHARE PRESENTED IN BAHT			
		THREE-MONTH PERIODS		SIX-MONTH PERIODS	
	Notes	2026	2025	2026	2025
REVENUES					
Revenues from medical treatment		539,138	573,024	1,074,146	1,154,781
Other income		937	1,771	8,003	7,424
Total Revenues		540,075	574,795	1,082,149	1,162,205
EXPENSES					
Cost of medical treatment		417,042	428,744	828,463	844,330
Selling expenses		941	903	2,061	1,974
Administrative expenses		78,789	79,819	157,670	159,693
Directors' remuneration	*11*	947	1,262	1,939	2,464
Total Expenses		497,719	510,728	990,133	1,008,461
Profit from operating activities		42,356	64,067	92,016	153,744
Finance income		3,785	5,566	8,258	11,897
Reversal allowance for expected credit loss		1,156	188	1,838	108
Unrealized gain (loss) on open-ended funds		3	(1)	7	(7)
Unrealized gain (loss) on marketable securities		33	(58)	216	(109)
Profit before Income Tax Expenses		47,333	69,762	102,335	165,633
Income Tax Expenses	*12*	(9,289)	(13,505)	(20,180)	(32,831)
Profit for the periods		**38,044**	**56,257**	**82,155**	**132,802**
Other Comprehensive Income (Loss) :-					
Other comprehensive income (loss) not to be reclassified to profit or loss in subsequent periods					
Loss on changes in value of marketable securities					
Loss recognized in other comprehensive income		(172)	(356)	(115)	(1,664)
Income tax on net change from the remeasuring of marketable securities		34	71	23	333
Loss on changes in value of marketable securities - net of tax		(138)	(285)	(92)	(1,331)
Other comprehensive loss for the periods - net of tax		(138)	(285)	(92)	(1,331)
Total comprehensive income for the periods		37,906	55,972	82,063	131,471
Earnings Per Share (Baht)					
Basic Earnings Per Share		**0.23**	**0.35**	**0.51**	**0.83**

The number of 160,000,000 common stocks used in computation.

Notes to the interim financial statements form an integral part of these statements.

UNAUDITED

REVIEWED

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026

THOUSAND BAHT

	Notes	Issued and paid-up share capital	Premium on common stocks	Retained earnings		Other components of shareholders' equity			Total shareholders' equity
						Other comprehensive income (loss)		Total other components of shareholders' equity	
				Legal reserve	Unappropriated	Gain on remeasuring of marketable securities	Actuarial gain from employee benefit plan		
Year 2026									
Balances as at January 1, 2026		160,000	172,000	16,000	2,444,426	4,055	20,603	24,658	2,817,084
Total comprehensive income (loss) for the period		-	-	-	82,155	(92)	-	(92)	82,063
Dividend payment	*11*	-	-	-	(166,400)	-	-	-	(166,400)
Balances as at June 30, 2026		160,000	172,000	16,000	2,360,181	3,963	20,603	24,566	2,732,747
Year 2025									
Balances as at January 1, 2025		160,000	172,000	16,000	2,386,871	5,073	20,603	25,676	2,760,547
Total comprehensive income (loss) for the period		-	-	-	132,802	(1,331)	-	(1,331)	131,471
Dividend payment	*11*	-	-	-	(219,200)	-	-	-	(219,200)
Balances as at June 30, 2025		160,000	172,000	16,000	2,300,473	3,742	20,603	24,345	2,672,818

Seummol.

Notes to the interim financial statements form an integral part of these statements.

UNAUDITED

REVIEWED

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED
STATEMENTS OF CASH FLOWS
FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026

	THOUSAND BAHT	
	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES :		
PROFIT FOR THE PERIOD	82,155	132,802
ADJUSTMENTS TO RECONCILE PROFIT FOR THE PERIOD		
TO NET CASH PROVIDED FROM (USED IN) OPERATION :-		
Income tax expenses	20,180	32,831
Depreciation	93,825	90,395
Amortization of deferred expenses	2,162	1,569
Amortization of computer softwares	3,876	3,852
Unrealized (gain) loss on open-ended funds	(7)	7
Unrealized (gain) loss on marketable securities	(216)	109
Loss on disposal of equipment	659	8
Bad debts	-	282
Reversal allowance for expected credit loss	(1,838)	(108)
Dividend income	(68)	(47)
Financial income	(8,258)	(11,897)
Long-term employee benefits expenses	7,058	6,878
PROFIT FROM OPERATION BEFORE CHANGE IN		
OPERATING ASSETS AND LIABILITIES ITEMS	199,528	256,681
(INCREASE) DECREASE IN OPERATING ASSETS ITEMS		
Trade and other current receivables	26,441	26,484
Inventories	(1,449)	5,297
Other current assets	101	25
Other non-current assets	(1,442)	(3,418)
DECREASE IN OPERATING LIABILITIES ITEMS		
Trade and other current payables	(7,533)	(25,726)
Assets acquisition payable	(20,752)	(8,600)
Other current liabilities	-	(15)
Cash received from operation	194,894	250,728
Interest income	6,044	11,671
Income tax paid	(34,237)	(46,757)
NET CASH PROVIDED FROM OPERATING ACTIVITIES	166,701	215,642

Notes to the interim financial statements form an integral part of these statements.

UNAUDITED

REVIEWED

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

STATEMENTS OF CASH FLOWS (CONTINUED)

FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2026

	THOUSAND BAHT	
	2026	2025
CASH FLOWS FROM INVESTING ACTIVITIES		
Decrease in other non-current financial assets	20,000	195,000
Increase in plant and equipment	(67,480)	(120,992)
Proceeds from disposal of equipment	660	548
Increase in intangible assets	(3,226)	(1,926)
Proceeds from dividend income	68	47
NET CASH PROVIDED FROM (USED IN) INVESTING ACTIVITIES	(49,978)	72,677
CASH FLOWS FROM FINANCING ACTIVITIES		
Dividend payment	(166,400)	(219,200)
NET CASH USED IN FINANCING ACTIVITIES	(166,400)	(219,200)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(49,677)	69,119
CASH AND CASH EQUIVALENTS AS AT JANUARY 1,	1,111,363	834,211
CASH AND CASH EQUIVALENTS AS AT JUNE 30,	1,061,686	903,330
ADDITIONAL DISCLOSURE ITEMS TO CASH FLOWS STATEMENTS		
Non-cash flows items comprise :		
Unrealized loss on marketable securities	115	1,664
Increase in plant and equipment from assets acquisition payable	3,326	33,604
Increase in equipment from retention	66	5,036

Seuumal.

Notes to the interim financial statements form an integral part of these statements.

NONTHAVEJ HOSPITAL PUBLIC COMPANY LIMITED

NOTES TO THE INTERIM FINANCIAL STATEMENTS

JUNE 30, 2026

1. GENERAL INFORMATION

1.1	Company status	A juristic person established under Thai law and listed on the Stock Exchange of Thailand.
1.2	Company location	432, Ngamvongwan Road, Tambol Bangkhen, Amphur Muangnonthaburi, Nonthaburi, Thailand.
	Branch	530, Rattanathibeth Road, Tambol Bangkrasor, Amphur Muangnonthaburi, Nonthaburi, Thailand.
1.3	Type of business	Hospital

2. BASIS FOR PREPARATION OF INTERIM FINANCIAL STATEMENTS

2.1 The interim financial statements are prepared on a condensed basis in accordance with Thai Accounting Standard No.34 : Interim Financial Reporting issued by the Federation of Accounting Professions and the Notification of the Office of Securities and Exchange Commission. These interim financial statements should be read in conjunction with the financial statements for the year ended December 31, 2025.

2.2 Accounting standards that became effective in the current accounting period

The Company has adopted the revised financial reporting standards, which are effective for fiscal years beginning on or after January 1, 2026. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards with most of the changes directed towards clarifying accounting treatment and providing accounting guidance for users of the standards.

These financial reporting standards do not have any significant impact on the financial statements of the Company.

2.3 These interim financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies and method of computation applied in these interim financial statements are consistent with those applied in the financial statements for the year ended December 31, 2025.

4. CASH AND CASH EQUIVALENTS

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31,2025
Cash	1,706	1,539
Bank deposits	1,059,980	1,109,824
Total	1,061,686	1,111,363

5. TRADE AND OTHER CURRENT RECEIVABLES

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
The trade accounts receivable are classified by outstanding balances of aging as follows :		
Current	202,373	229,943
Overdue within 3 months	8,278	10,458
Over 3 - 6 months	1,792	1,992
Over 6 - 12 months	451	1,320
Over 12 months	8,306	9,149
Total	221,200	252,862
Less Allowance for expected credit loss	(9,560)	(11,398)
Total trade receivables - net	211,640	241,464
Other current receivables		
Prepaid expenses	23,638	19,273
Other	9,852	6,782
Total other current receivables	33,490	26,055
Total trade and other current receivables	245,130	267,519

6. INVENTORIES

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Medicines and medical supplies	50,291	49,940
General supplies	11,365	10,267
Total	61,656	60,207

7. OTHER CURRENT FINANCIAL ASSETS

7.1 Open-ended Fund

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Open-ended Fund	47	47
Valuation adjustment	(17)	(24)
Open-ended Fund-Fair value	30	23

PARTICULARS	THOUSAND BAHT			
	For the periods ended June 30,			
	three-months		six-months	
	2026	2025	2026	2025
Unrealized gain (loss) on investments in open-ended fund	3	(1)	7	(7)

7.2 Marketable securities

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Acquisition cost	2,008	2,008
Valuation adjustment	(1,020)	(1,236)
Fair value at ending periods	988	772

PARTICULARS	THOUSAND BAHT			
	For the periods ended June 30,			
	three-months		six-months	
	2026	2025	2026	2025
Unrealized gain (loss) on marketable securities	33	(58)	216	(109)

8. OTHER-NON-CURRENT FINANCIAL ASSETS

8.1 Marketable securities

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Acquisition cost	222	222
Valuation adjustment	4,954	5,069
Fair value at ending periods	5,176	5,291

PARTICULARS	THOUSAND BAHT			
	For the periods ended June 30,			
	three-months		six-months	
	2026	2025	2026	2025
Loss on changes in value of marketable securities	172	356	115	1,664

8.2 Other investment

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Savings lottery (due January 13, 2027/February 19, 2027)	125,000	125,000
Savings lottery (due October 3, 2026/November 29, 2026)	150,000	150,000
Total	275,000	275,000
Current portion	(275,000)	(150,000)
Total	-	125,000

8.3 Fixed deposit at bank

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Fixed deposit at bank 24 months	100,000	120,000
Interest rate per annum	1.90	1.90-2.20
Accrued interest	286	286

9. TRADE AND OTHER CURRENT PAYABLES

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Trade accounts payables	73,726	89,033
Accrued expenses	33,978	23,007
Accrued doctors' fees	73,918	79,028
Others	29,102	27,123
Total	210,724	218,191

10. NON-CURRENT PROVISIONS FOR EMPLOYEE BENEFITS

Non-current provisions for employee benefits as at June 30, 2026 and December 31, 2025 which are compensations on employees' retirement, are as follows

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Defined benefit obligation at beginning balances	81,004	78,508
Add Current service cost	6,234	11,741
Interest cost	824	1,566
Less Benefits paid during the period	-	(10,811)
Defined benefit obligation at ending balances	88,062	81,004

The key assumptions used in determining the employee benefits are shown as follows:

PARTICULARS	As at June 30, 2026 and December 31, 2025
Discount rate	2.18 % per annum
Salary increase rate	4.0 - 4.5 % per annum
Staff turnover rate	7 - 24 % per annum

11. DIVIDEND PAYMENT AND DIRECTOR'S REMUNERATION

On February 20, 2026, the Board of Directors' Meeting was held and has a resolution to pay dividend at Baht 1.04 per share to the shareholders of 160 million shares, totalling Baht 166.40 million. On April 24, 2026, the Ordinary General Shareholders' Meeting was held and approved a resolution to pay such proposed dividend, including directors' remuneration amounting to Baht 2.77 million, and annual meeting allowance as specified. The Company has paid dividend on May 22, 2026.

On February 17, 2025, the Board of Directors' Meeting was held and has a resolution to pay dividend at Baht 1.37 per share to the shareholders of 160 million shares, totalling Baht 219.20 million. On April 25, 2025, the Ordinary General Shareholders' Meeting was held and approved a resolution to pay such proposed dividend, including directors' remuneration amounting to Baht 3.61 million, and annual meeting allowance as specified. The Company has paid dividend on May 23, 2025.

12. INCOME TAXES

Corporate income tax of the Company for the three-month and six-month periods ended June 30, 2026 and 2025 are calculated from the accounting profits and adjusted with other revenues and some expenses which are exempted from income tax or being disallowable expenses in corporate income tax computation.

The Company income taxes are calculated at the rate of 20 percent.

Income tax expenses recognized in statements of comprehensive income consist:

FOR THE PERIODS ENDED JUNE 30,	THOUSAND BAHT	
	2026	2025
For 3 month periods		
Corporate income tax for the periods	9,750	14,160
Amortization and reversal of temporary differences		
assets/liabilities on temporary differences	(461)	(655)
Income tax expenses	9,289	13,505
For 6 month periods		
Corporate income tax for the periods	21,179	34,208
Amortization and reversal of temporary differences		
assets/liabilities on temporary differences	(999)	(1,377)
Income tax expenses	20,180	32,831

As at June 30, 2026 and December 31, 2025, the deferred tax assets/liabilities arose from the following temporary differences:

PARTICULARS	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Temporary differences in the statements of comprehensive income		
Allowance for adjustment investment value in Open-ended Fund	17	24
Allowance for adjustment in market securities -other current financial assets	1,020	1,236
Allowance for expected credit loss	9,560	11,398
Provision for long-term employee benefits	113,816	106,758
Total	124,413	119,416
Temporary differences in other comprehensive income		
- Recognized in other components of shareholders' equity		
Allowance for adjustment in market securities -other non-current financial assets	(4,954)	(5,069)
Gains on re-measurements of defined benefit plans	(25,754)	(25,754)
Total	93,705	88,593
Deferred tax assets calculated from tax rate of 20%.	18,741	17,719

13. FINANCIAL INFORMATION BY SEGMENT

The Company is engaged in the business of medical treatment in one geographical area, Thailand. Therefore, the financial information by segment is not shown in these financial statements.

14. COMMITMENT

14.1 As at June 30, 2026 and December 31, 2025, the Company has commitment from the issuance of bank guarantee as follow :

PARTICULAR	THOUSAND BAHT	
	As at June 30, 2026	As at December 31, 2025
Letters of guarantee issued by commercial bank	4,277	4,277

14.2 Commitment under service agreement

As at June 30, 2026, the Company has entered into service agreements which can be cancelled when the counter party has prior notice 30 to 60 days in advance the amount of Baht 5.43 million.

14.3 Capital expenditure commitments

As at June 30, 2026, the Company has capital expenditure commitments to pay a total of Baht 66.51 million in regarding to the improvement of system and construction project.

15. FINANCIAL STATEMENTS APPROVAL

These interim financial statements are duly approved by the Company's Board of Directors on August 11, 2026.